Compare · ABOS vs ALZN
ABOS vs ALZN
Side-by-side comparison of Acumen Pharmaceuticals Inc. (ABOS) and Alzamend Neuro Inc. (ALZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ABOS focuses on Biotechnology: Biological Products (No Diagnostic Substances), while ALZN focuses on Biotechnology: Pharmaceutical Preparations.
- ABOS is the larger of the two at $15.1M, about 2.5x ALZN ($6.0M).
- ABOS has been more active in the news (10 items in the past 4 weeks vs 1 for ALZN).
- ABOS has more recent analyst coverage (14 ratings vs 1 for ALZN).
- Company
- Acumen Pharmaceuticals Inc.
- Alzamend Neuro Inc.
- Price
- -
- -
- Market cap
- $15.1M
- $6.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2021
- News (4w)
- 10
- 1
- Recent ratings
- 14
- 1
Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Alzamend Neuro Inc.
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Latest ABOS
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits
- Acumen Pharmaceuticals downgraded by BofA Securities with a new price target
- Acumen Pharmaceuticals downgraded by Stifel with a new price target
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
- SEC Form EFFECT filed by Acumen Pharmaceuticals Inc.
- SEC Form S-3 filed by Acumen Pharmaceuticals Inc.
- SEC Form 10-Q filed by Acumen Pharmaceuticals Inc.
- SEC Form 8-K filed by Acumen Pharmaceuticals Inc.
- Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Latest ALZN
- Amendment: Alzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form RW filed by Alzamend Neuro Inc.
- Alzamend Neuro Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
- SEC Form 10-Q filed by Alzamend Neuro Inc.
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Director Ault Milton C Iii sold $3,116 worth of shares (2,000 units at $1.56), closing all direct ownership in the company (SEC Form 4)
- SEC Form PRE 14A filed by Alzamend Neuro Inc.
- SEC Form S-1 filed by Alzamend Neuro Inc.